profit from every $100 of sales.
$0$100
Aspire Biopharma Holdings
$0.01-29.06% today
-85.0% in 1 year
1-year low $0.011-year high $0.09
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Aspire Biopharma Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Aspire Biopharma Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Aspire Biopharma Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 0.2×
- 18.7×
- –
- 0.9×
- -2,503.3%
- -1,338.2%
- 0.0%
Profitability
- 16.3%
- -15,745.9%
- -34,040.6%
- -15,471.2%
- -121.9%
- 1,018.3%
- 199.4%
- -165.3%
- -137.2%
- 2,771.1%
Growth
- –
- –
- −1,756.6%
- –
- +21.6%
Financial health
- 1.0×
- 0.13
- 7.0%
- -0.8×
- 2.26
- 2.14
- 0.00
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
73Pass
Philip Fisher
28No pass
Peter Lynch
–Not enough data
Joel Greenblatt
52No pass
Charlie Munger
22No pass
Terry Smith
16No pass
Questions about Aspire Biopharma Holdings
Is Aspire Biopharma Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aspire Biopharma Holdings AI analysis
What does Aspire Biopharma Holdings do?
Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. It is in Biotechnology.
Does Aspire Biopharma Holdings pay a dividend?
No. Aspire Biopharma Holdings does not pay a dividend at the moment.
How has Aspire Biopharma Holdings stock done over the past year?
Down 85.0% over the past twelve months, to $0.01. It traded between $0.01 and $0.09 and is 86.2% below its high.
Who are Aspire Biopharma Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Aspire Biopharma Holdings's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.